Chugai Seiyaku Kabushiki Kaisha

Xencor, Inc.

University of Miyazaki

Masamichi Sugimoto

Hiroaki Ito

Tadamitsu Kishimoto

Hidetomo Kitamura

Hisafumi Okabe

Norihiro Nishimoto

Kenichi Akamatsu

Kazuyuki Yoshizaki

Shigeyuki Iijima

Izumi Sugo

Shin Shimaoka

Gregory Alan Lazar

Bassil I Dahiyat

Masami Suzuki

Atsuhiko Kato

Kiyotaka Nakano

Yasuko Kinoshita

Takahiro Ishiguro

Megumi Tanaka

Hiroaki Kataoka

Hirotake Takai

An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.

Anti-glypican-3 antibody

The present invention relates to an in-vitro immunoassay method for detecting the presence of liver cancer cells in a subject. In the method of the present invention, antigen retrieval treatment based on heat-induced epitope retrieval method and antigen retrieval treatment based on protease-induced epitope retrieval method can be combined in the detection of glypican 3 antigen expression in liver cancer tissues to thereby detect the difference in the expression level or expression pattern of the glypican 3 antigen by immunohistochemical staining method. This enables samples, which has been determined by the conventional HIER method as highly expressing glypican 3, to be graded according to the expression level of glypican 3.

Method for detection of liver cancer cell using anti-glypican-3 antibody

A method for treating psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Method for treating psoriasis by administering an antibody to interleukin-6 receptor

A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Method of treating psoriatic arthritis with an IL-6 receptor antibody

The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.

Adjuvant therapy with the use of anti-glypican 3 antibody

An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.

Anti-glypican 3 antibody having modified sugar chain

A preventive and therapeutic agent for psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist

Growing community of inventors

Kanagawa, Japan

Masamichi Sugimoto